The Joint Council of Practitioners (JCCP) has published Standard Operating Procedure (SOP) for non-surgical cosmetic injectable treatments on their official website.
The SOP is based on Fakih-Gomez et al. Updated Filler Emergency Kit: Next-Generation Emergency Solution, a peer-reviewed article published in Aesthetic Plastic Surgery and indexed on PubMed. It is not regulatory framework and has not been endorsed by any UK regulatory body.
Following criticism from the specialty, the Aesthetic Complications Expert (ACE) Group World released a summary response outlining inaccuracies and comments that “contravene evidence-based practice in the document.” The organisation stated its aim was to ensure members were protected and provided with accurate guidance.
Corrections highlighted by ACE Group World included recommendations for a stat dose of 300mg aspirin followed by 75mg daily, in contrast to the SOP’s suggestion of 100mg for vascular support. The group also noted that prednisolone is not routinely recommended in the treatment of vascular occlusion, particularly in the acute phase, and added that the 20mg dose cited in the SOP is “not supported by ACE Group World.”
The JCCP has since issued a disclaimer for the SOP, which was shared by ACE Group World. In a statement to Aesthetics, the JCCP clarified, “The piece was published as an independent key opinion publication and does not in any way change the JCCP’s previously published standards. A disclaimer was published to avoid any misinterpretation by readers regarding the status of this SOP and to confirm that will be for practitioners to make their own interpretation of the guidance included therein. The JCCP has not formally approved this SOP for adoption. Readers should apply their clinical and professional judgement regarding the applicability of this SOP to their own practice in accordance with other reputable evidence-based practice recommendations. The JCCP asserts that the guidance provided in its JCCP/CPSA Competency Framework and standards published in 2018 continues to be its accepted and recommended position.”
The JCCP also confirmed that the key opinion author has been made aware of the feedback received and that further response is awaited.